4569 research outputs found
Sort by
Artificial intelligence-based classification of peripheral blood nucleated cells using label-free imaging flow cytometry
Get PDF浜松医科大学博士（医学）doctoral医学系研究科thesi
Intraocular pressure at different gaze positions in patients with highly myopic strabismus
Get PDF浜松医科大学博士（医学）doctoral医学系研究科thesi
Patterns of involvement of digits in patients with multiple trigger digits: A retrospective study
Get PDF浜松医科大学博士（医学）doctoral医学系研究科thesi
Risk factors for coronal oblique take-off following adult spinal deformity surgery using lateral lumbar interbody fusion and open posterior corrective fusion
Get PDF浜松医科大学博士（医学）doctoral医学系研究科thesi
Comparison of operative outcomes between monopolar and bipolar coagulation in hepatectomy: a propensity score-matched analysis in a single center
Get PDF浜松医科大学博士（医学）doctoral医学系研究科thesi
Association between remimazolam and postoperative delirium in older adults undergoing elective cardiovascular surgery: a prospective cohort study
Get PDFPurpose: Postoperative delirium is one of the most common complications after cardiovascular surgery in older adults. Benzodiazepines are a reported risk factor for delirium; however, there are no studies investigating remimazolam, a novel anesthetic agent. Therefore, we prospectively investigated the effect of remimazolam on postoperative delirium.
Methods: We included elective cardiovascular surgery patients aged ≥ 65 years at Hamamatsu University Hospital between August 2020 and February 2022. Patients who received general anesthesia with remimazolam were compared with those who received other anesthetics (control group). The primary outcome was delirium within 5 days after surgery. Secondary outcomes were delirium during intensive care unit stay and hospitalization, total duration of delirium, subsyndromal delirium, and differences in the Mini-Mental State Examination scores from preoperative to postoperative days 2 and 5. To adjust for differences in the groups’ baseline covariates, we used stabilized inverse probability weighting as the primary analysis and propensity score matching as the sensitivity analysis.
Results: We enrolled 200 patients; 78 in the remimazolam group and 122 in the control group. After stabilized inverse probability weighting, 30.3% of the remimazolam group patients and 26.6% of the control group patients developed delirium within 5 days (risk difference, 3.8%; 95% confidence interval, −11.5% to 19.1%; p=0.63). The secondary outcomes did not differ significantly between the groups, and the sensitivity analysis results were similar to those for the primary analysis.
Conclusion: Remimazolam was not significantly associated with postoperative delirium compared with other anesthetic agents.journal articl
第34回 静岡県母性衛生学会学術集会プログラム
Get PDF特別講演：題目 “プレコンセプションケア”
一般演題
第一群：
1. 胎児適応で選択的帝王切開分娩となった褥婦の出産体験の振り返りを通してケア方法を検討する
2. 小児専門病院産科病棟で誕生した児をもつ父親が必要としているケアについての検討
第二群：
3. 4か月児を育てる母親が捉えた、「母親の自立」に関する構成因子 -第1報-
4. 妊娠期における産後うつ病を予防するための看護職による効果的な支援に関する文献検討
5. 流産・死産・乳児死亡経験者に対するアンズスマイルの活動報告
第三群：
6. 13歳妊娠の一例
7. 県内における新生児に対するビタミンK予防投与の現状
8. COVID-19感染妊婦の分娩に関する当院の対応についてconference pape
Prevention of Atopic Dermatitis in High-risk Neonates via Different Types of Moisturizer Application: a Randomized, Blinded, Parallel, Three-group, Phase II Trial (PAF study)
Get PDFBackground
The effectiveness of moisturizers in preventing infant atopic dermatitis (AD) remains unclear. We previously showed that using 2e moisturizer of commercial moisturizer (Shiseido Japan Co., Ltd., Tokyo, Japan) at least once a day significantly prevented AD in infants as compared with as-needed petroleum jelly. This trial aimed to determine the effectiveness of twice- or once-daily application of Fam’s Baby moisturizer (Fam’s Inc., Tokyo, Japan) in preventing AD compared with once-daily 2e moisturizer.
Methods
This trial was a single-center, three-parallel-group, assessor-blinded, superiority, individually randomized, controlled, phase II trial that was conducted from August 25, 2020 to September 28, 2021. We randomly assigned 60 newborns with at least one parent or sibling who has AD to receive Fam’s Baby moisturizer twice daily (Group A) or once daily (Group B), or 2e once daily (Group C) in a 1:1:1 ratio until they were 32 weeks old. The primary outcome was the time to AD onset.
Results
AD was observed in 11/20 (55%), 5/20 (25%), and 10/20 (50%), infants in Groups A, B, and C, respectively. Cumulative incidence values for AD according to the Kaplan–Meier method showed that infants in Group B tended to maintain an intact skin for a longer period than those in Group C (median time, not reached [NR] vs. 212 days, log-rank test, p=0.064). Cox regression analysis showed that the risk of AD tended to be lower in Group B (hazard ratio with group C as control, 0.36; 95% confidential intervals: 0.12–1.06). No serious adverse events occurred in any of the enrolled infants.
Conclusion
Fam’s Baby moisturizer may better prevent AD than 2e. Further large-scale trials should be performed to confirm the efficacy of Fam’s Baby moisturizer in preventing AD in infants